| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Asymchem Laboratories (Tianjin) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥75.98 |
| 52 Week High | CN¥164.86 |
| 52 Week Low | CN¥59.55 |
| Beta | 0.17 |
| 11 Month Change | 19.18% |
| 3 Month Change | 11.90% |
| 1 Year Change | -50.88% |
| 33 Year Change | -73.58% |
| 5 Year Change | -12.38% |
| Change since IPO | 383.95% |
Recent News & Updates
Estimating The Intrinsic Value Of Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821)
Oct 15
Investors Still Aren't Entirely Convinced By Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Earnings Despite 25% Price Jump
Sep 28Recent updates
Estimating The Intrinsic Value Of Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821)
Oct 15Investors Still Aren't Entirely Convinced By Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Earnings Despite 25% Price Jump
Sep 28Is There An Opportunity With Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) 49% Undervaluation?
Jul 16Asymchem Laboratories (Tianjin) (SZSE:002821) Is Paying Out A Dividend Of CN¥1.80
Jun 27Benign Growth For Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Underpins Its Share Price
Jun 26Does Asymchem Laboratories (Tianjin) (SZSE:002821) Have A Healthy Balance Sheet?
May 22Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Just Missed Earnings: Here's What Analysts Think Will Happen Next
Apr 03Downgrade: Here's How Analysts See Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Performing In The Near Term
Apr 02A Look At The Fair Value Of Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821)
Mar 26Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 04Shareholder Returns
| 002821 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.8% | 1.6% | 2.7% |
| 1Y | -50.9% | 0.7% | 4.6% |
Return vs Industry: 002821 underperformed the CN Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: 002821 underperformed the CN Market which returned 4.6% over the past year.
Price Volatility
| 002821 volatility | |
|---|---|
| 002821 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in CN Market | 11.5% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 002821 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002821's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 9,300 | Hao Hong | www.asymchem.com.cn |
Asymchem Laboratories (Tianjin) Co., Ltd. engages in the provision of contract development and manufacturing services focuses on innovation and commercial application of global pharmaceutical technology in Mainland China and internationally. The company offers research and development, and production services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services.
Asymchem Laboratories (Tianjin) Co., Ltd. Fundamentals Summary
| 002821 fundamental statistics | |
|---|---|
| Market cap | CN¥26.32b |
| Earnings (TTM) | CN¥1.08b |
| Revenue (TTM) | CN¥5.90b |
24.9x
P/E Ratio4.6x
P/S RatioIs 002821 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002821 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.90b |
| Cost of Revenue | CN¥3.23b |
| Gross Profit | CN¥2.67b |
| Other Expenses | CN¥1.59b |
| Earnings | CN¥1.08b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | 3.05 |
| Gross Margin | 45.20% |
| Net Profit Margin | 18.33% |
| Debt/Equity Ratio | 0% |
How did 002821 perform over the long term?
See historical performance and comparison